Comparative Pharmacology
Head-to-head clinical analysis: TIOTROPIUM BROMIDE versus VESICARE LS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TIOTROPIUM BROMIDE versus VESICARE LS.
TIOTROPIUM BROMIDE vs VESICARE LS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tiotropium bromide is a long-acting, competitive, and reversible muscarinic receptor antagonist (anticholinergic). It binds preferentially to M3 receptors in the smooth muscle of the bronchi, inhibiting acetylcholine-mediated bronchoconstriction and mucus secretion, leading to prolonged bronchodilation.
Competitive antagonist at muscarinic acetylcholine receptors (M1–M5), with high selectivity for M3 receptors in the bladder detrusor muscle. Reduces involuntary bladder contractions and increases bladder capacity.
Inhalation (oral): 18 mcg once daily via HandiHaler; or 2.5 mcg (2 puffs) once daily via Respimat inhaler.
5 mg orally once daily; may increase to 10 mg once daily.
None Documented
None Documented
Terminal elimination half-life: 5–6 days (inhalation). Longer half-life allows once-daily dosing. Steady-state reached in 2–3 weeks.
Terminal elimination half-life: 45 hours (range 32–68 h). Extended half-life allows once-daily dosing; steady-state reached in ~10 days.
Primarily renal: 14% of dose excreted unchanged in urine; remainder as inactive metabolites via biliary/fecal (70%) and renal (30% total).
Renal: 68% (unchanged drug ~59%, metabolites ~9%), Fecal: 24% (metabolites), Biliary: negligible.
Category A/B
Category C
Anticholinergic
Anticholinergic